Last reviewed · How we verify
Placebo soft capsule
Placebo soft capsule is a Small molecule drug developed by Capital Medical University. It is currently in Phase 3 development. Also known as: Placebo.
This drug is a placebo, meaning it has no active therapeutic effect.
Placebo is a type of intervention used in clinical trials for various conditions, including Juvenile Idiopathic Arthritis, Dry Eye Syndrome, Prostatic Hyperplasia, Sickle Cell Disease, and Alcohol Use Disorder. Placebo is classified as an INHIBITOR, specifically a peptidoglycan inhibitor, which targets proteins.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Placebo soft capsule |
|---|---|
| Also known as | Placebo |
| Sponsor | Capital Medical University |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not interact with any biological molecules or systems. It is used as a control in clinical trials to compare the effects of active treatments.
Approved indications
Common side effects
Key clinical trials
- FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM) (PHASE2)
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- Efficacy and Safety of Butylphthalide Soft Capsule for the Treatment of Vascular Dementia (PHASE3)
- Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema (PHASE2, PHASE3)
- The Effect of Oral Use of Lyophilised Royal Jelly on Cognitive Functions and Immune System in Elderly Individuals (NA)
- The Efficacy of Tocotrienol Rich Fraction for Liver Protection in Adult Patients With Alcoholic Fatty Liver Disease (AFLD) (PHASE2)
- Do Discounted Vouchers for Medical Cannabis Reduce Opioid Use in Adults With Pain (NA)
- Study of CU06-1004 in Patients With Daibetic Macular Edema (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo soft capsule CI brief — competitive landscape report
- Placebo soft capsule updates RSS · CI watch RSS
- Capital Medical University portfolio CI
Frequently asked questions about Placebo soft capsule
What is Placebo soft capsule?
How does Placebo soft capsule work?
Who makes Placebo soft capsule?
Is Placebo soft capsule also known as anything else?
What development phase is Placebo soft capsule in?
Related
- Manufacturer: Capital Medical University — full pipeline
- Also known as: Placebo
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing